Revenues from the company's medical devices segment grew 12% in the quarter, fueled by double-digit gains in diabetes care, heart failure, electrophysiology, and rhythm management, with continuous ...
Abbott Laboratories(NYSE:ABT) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback